David J Ponting
Overview
Explore the profile of David J Ponting including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas R, Ponting D, Thresher A, Schlingemann J, Wills J, Johnson G
Arch Toxicol
. 2025 Jan;
99(3):983-993.
PMID: 39751876
The tumorigenic dose 50 (TD) is a widely used measure of carcinogenic potency which has historically been used to determine acceptable intake limits for carcinogenic compounds. Although broadly used, the...
2.
Ponting D, Czich A, Felter S, Glowienke S, Harvey J, Nudelman R, et al.
Regul Toxicol Pharmacol
. 2024 Dec;
156:105762.
PMID: 39662665
The carcinogenic potency categorisation approach (CPCA) has recently been introduced by health authorities. In this model, structural features from recent literature, industry proposals, and analyses performed by health authorities, provide...
3.
Kidd D, Crooks I, Saccardo A, Ponting D, Kocks G, Gandhi R, et al.
Mutagenesis
. 2024 Oct;
PMID: 39447060
The proceedings of the 36th annual meeting of the Industrial Genotoxicology Group (IGG) are shared here. The meeting held at Lhasa Limited, Leeds, UK on 28th November 2023, focussed two...
4.
Ndreu L, Carlsson J, Ponting D, Niklasson I, Steen E, McHugh L, et al.
Front Toxicol
. 2024 Jul;
6:1398852.
PMID: 39050368
Background: Cinnamic alcohol is a natural compound, widely used in fragrances, which can cause allergic contact dermatitis. Cinnamic alcohol lacks intrinsic reactivity and autoxidation or metabolic activation is necessary for...
5.
Bercu J, Ponting D, Ripp S, Dobo K, Totah R, Bolleddula J
Clin Pharmacol Ther
. 2024 Mar;
116(1):34-37.
PMID: 38494918
No abstract available.
6.
Snodin D, Trejo-Martin A, Ponting D, Smith G, Czich A, Cross K, et al.
Chem Res Toxicol
. 2024 Feb;
37(2):181-198.
PMID: 38316048
A thorough literature review was undertaken to understand how the pathways of -nitrosamine transformation relate to mutagenic potential and carcinogenic potency in rodents. Empirical and computational evidence indicates that a...
7.
Thomas R, Oliveira A, Ponting D, Thresher A
Toxicol Lett
. 2023 Nov;
390:1-4.
PMID: 37923025
The Tumorigenic dose 50 (TD) is a widely used measure of carcinogenic potency representing the dosage at which 50 % of animals exposed to a compound will develop tumours. The...
8.
Fine J, Allain L, Schlingemann J, Ponting D, Thomas R, Johnson G
Regul Toxicol Pharmacol
. 2023 Oct;
145:105505.
PMID: 37805106
N-nitrosamines (NAs) are a class of compounds of which many, especially of the small dialkyl type, are indirect acting DNA alkylating mutagens. Their presence in pharmaceuticals is subject to very...
9.
Burns M, Ponting D, Foster R, Thornton B, Romero N, Smith G, et al.
J Pharm Sci
. 2023 Oct;
112(12):3005-3011.
PMID: 37805074
N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of...
10.
Tennant R, Ponting D, Thresher A
Regul Toxicol Pharmacol
. 2023 Jul;
143:105460.
PMID: 37495012
Mutagenicity data is a core component of the safety assessment data required by regulatory agencies for acceptance of new drug compounds, with the OECD-471 bacterial reverse mutation (Ames) assay most...